2. Anti-infection
  3. Arenavirus
  4. Arevirumab

Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever.

For research use only. We do not sell to patients.

Arevirumab

Arevirumab Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Arevirumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Lassa virus
In Vivo

Arevirumab-3 (15 mg/kg of each monoclonal antibody in the cocktail; i.v.; days 8, 11, and 14 post-challenge) provides 100% survival to cynomolgus macaques with advanced Lassa fever caused by LASV lineage II strain 0043/LV/14, and significantly reduces viral loads in circulation and tissues[1].
Arevirumab-3 (15 mg/kg of each monoclonal antibody in the cocktail; i.v.; days 8, 11, and 14 post-challenge) provides 100% survival to cynomolgus macaques with advanced Lassa fever caused by LASV lineage III strain Ojoko, and significantly reduces viral loads in circulation and tissues[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Macaca fascicularis (healthy adult, Asian origin, male and female, age ~4 to 5.5 y, weight 3.0 to 5.2 kg)[1]
Dosage: 15 mg/kg of each monoclonal antibody (8.9F, 12.1F, 37.2D) in the Arevirumab-3 cocktail
Administration: i.v.; days 8, 11, and 14 post-challenge
Result: Ensured 100% survival of all 5 treated macaques at study end.
Cleared infectious LASV from circulation by day 11 post-challenge in all treated animals.
Eliminated circulating viral genomic RNA (vRNA) in all treated animals by day 21 post-challenge.
Reduced tissue vRNA levels significantly compared to untreated control (multiplicity-adjusted P ≤ 0.020 for all assayed tissues).
Caused a significant difference in peak viremia (measured by both vRNA and infectious virus) between treated animals and control cohorts (P = 0.004 and P = 0.007, respectively).
Animal Model: Macaca fascicularis (healthy adult, Asian origin, male and female, age ~3 to 7 y, weight 3.0 to 5.4 kg)[1]
Dosage: 15 mg/kg of each monoclonal antibody (8.9F, 12.1F, 37.2D) in the Arevirumab-3 cocktail
Administration: i.v.; days 8, 11, and 14 post-challenge
Result: Ensured 100% survival of all 5 treated macaques at study end.
Cleared infectious LASV from circulation by day 14 post-challenge in all treated animals.
Eliminated circulating vRNA in all treated animals by day 14 post-challenge.
Reduced tissue vRNA levels significantly compared to untreated control (multiplicity-adjusted P ≤ 0.031 for most assayed tissues).
Caused a significant difference in peak vRNA load between the Arevirumab-3 cohort and controls (multiplicity-adjusted P = 0.027).
Target

GPC
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[Arevirumab]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Arevirumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ArevirumabArevirumab-3Arevirumab3Arevirumab 3ArenavirusLassa feverLassa virus (LASV)cynomolgus macaquesmembrane fusionLASV glycoprotein complex (GPC)viral genomic RNALASV lineage II isolate 0043/LV/14matriglycanlate endosomal infection stepsLASV lineage III isolate OjokoInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Arevirumab
Cat. No.:
HY-P992155
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.